This information is current as of April 14, 2017.

An-Jiang Wang, Zhonghan Yang, Viktoriya Grinchuk, Allen Smith, Bolin Qin, Nonghua Lu, Duan Wang, Hongbing Wang, Thirumalai R. Ramalingam, Thomas A. Wynn, Joseph F. Urban, Jr., Terez Shea-Donohue and Aiping Zhao

*J Immunol* published online 30 September 2015
http://www.jimmunol.org/content/early/2015/09/30/jimmunol.1500337

---

**Supplementary Material**
http://www.jimmunol.org/content/suppl/2015/09/30/jimmunol.1500337.DCSupplemental

**Subscription**
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

**Permissions**
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
IL-25 or IL-17E Protects against High-Fat Diet–Induced Hepatic Steatosis in Mice Dependent upon IL-13 Activation of STAT6

An-Jiang Wang,*†‡,1 Zhonghan Yang,*†‡,1 Viktoriya Grinchuk,*† Allen Smith,‡ Bolin Qin,* Nonghua Lu,‡ Duan Wang,† Hongbing Wang,‖ Thirumalai R. Ramalingam,‡ Thomas A. Wynn,‡ Joseph F. Urban, Jr.,‡ Terez Shea-Donohue,*† and Aiping Zhao*†

IL-25 or IL-17E is a member of IL-17 cytokine family and has immune-modulating activities. The role of IL-25 in maintaining lipid metabolic homeostasis remains unknown. We investigated the effects of exogenous IL-25 or deficiency of IL-25 on hepatic lipid accumulation. IL-25 expression was examined in paraffin-embedded tissue sections of liver from patients or in the livers from mice. Mouse model of steatosis was induced by feeding a high-fat diet (HFD). Extent of steatosis as well as expression of cytokines, key enzymes for lipid metabolic pathways, markers for Kupffer cells/macrophages, and lipid droplet (LD) proteins, were analyzed. Our results show that hepatic steatosis in mice was accompanied by increased LD proteins, but decreased IL-25 in the liver. Decreased hepatic IL-25 was also observed in patients with fatty liver. Administration of IL-25 to HFD-fed wild-type mice led to a significant improvement in hepatic steatosis. This effect was associated with increased expression of IL-13, development of alternatively activated Kupffer cells/macrophages, and decreased expression of LD proteins in the liver. In contrast, administration of IL-25 to HFD-fed mice deficient in STAT6 or IL-13 had no effects. In addition, stimulation of primary hepatocytes with IL-13, but not IL-25, resulted in downregulation of LD proteins. Finally, mice deficient in IL-25 had exacerbated hepatic lipid accumulation when fed the HFD. These data demonstrate that dysregulated IL-25 expression contributes to lipid accumulation, whereas exogenous IL-25 protects against hepatic steatosis through IL-13 activation of STAT6. IL-25 and IL-13 are potential therapeutic agents for hepatic steatosis and associated pathologies. The Journal of Immunology, 2015, 195: 000–000.
TNFR-associated factor 6 may be involved, and the signaling events initiated by binding to IL-17RB are likely to be tissue/cell specific (5). Recent studies demonstrated that IL-25 acts primarily on type 2 innate lymphoid cells (ILC2) to induce the production of the type 2 cytokines IL-13 and IL-5 (6). It is critical for host protective immunity against parasitic nematode infection and is also associated with airway allergic inflammation (7–9). Recent studies demonstrated that IL-25 acts primarily on type 2 innate lymphoid cells (ILC2) to induce the production of the type 2 cytokines IL-13 and IL-5 (6). It is critical for host protective immunity against parasitic nematode infection and is also associated with airway allergic inflammation (7–9). Of equal importance is the ability of IL-25 to inhibit proinflammatory Th1 and Th17 cytokine responses that are implicated in the metabolic manifestation associated with obesity (10). Therefore, IL-25 is emerging as a key regulator of inflammation. The highest levels of IL-25 are found in the gastrointestinal tract and lung, where it is expressed primarily by epithelial cells and certain types of immune cells (8, 9, 11–13). More recently, a study showed that hepatocytes were capable of producing IL-25, and decreased hepatic IL-25 was observed in animals or humans with hepatitis (14). Whether IL-25 is involved in regulation of lipid metabolism and associated hepatic steatosis is not known.

Given that inflammation affects the progression of NAFLD, whereas IL-25 possesses anti-inflammatory properties, we hypothesized that constitutively expressed IL-25 maintains lipid metabolic homeostasis in mice; enhanced IL-25 production in vivo would protect against the excessive lipid accumulation in the liver. The present study was designed to investigate: 1) the effects of exogenous IL-25 on obesity-associated hepatic steatosis in mice; 2) the molecular mechanisms of IL-25 regulation of lipid accumulation/storage; 3) the contribution of the IL-13–STAT6 axis to the effects of IL-25; and 4) the impact of IL-25 deficiency on expression of hepatic steatosis.

Materials and Methods

Mice and diet

C57BL/6 wild-type (WT) mice were purchased from the National Cancer Institute Mouse Repository (Frederick, MD). Mice deficient in STAT6 (STAT6−/−; The Jackson Laboratory) or IL-13 (IL-13−/−; National Institutes of Allergy and Infectious Diseases Taconic contract) on C57BL/6 background were bred in the U.S. Department of Agriculture/Beltsville animal facility. Mice deficient in IL-25 (IL-25−/−) were generated by Regeneron Pharmaceuticals (Tarrytown, NY) and backcrossed to C57BL/6 mice for 10 generations. A commonly used high-fat diet (HFD)–fed mouse model of hepatic steatosis was selected because it is considered physiologically relevant. Male 5-wk-old mice were fed an HFD (60% of kcal from fat; Research Diet, New Brunswick, NJ) or normal control diet (NCD; 10% of kcal from fat) ad libitum. These studies were conducted with institutional approval from both the University of Maryland, Baltimore and the U.S. Department of Agriculture Beltsville Area Animal Care and Use Committees (protocol #13-003), in accordance with principles set forth in the Guide for Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources, National Research Council, Health and Human Services Publication.

Administration of IL-25

After being on the respective diet for ∼14 wk, mice were separated into treatment or control groups. Mice in the treatment group were injected i.p. with 1 mg mouse rIL-25 (R&D Systems, Minneapolis, MN) in 100 µl PBS daily for 5 d in the first week followed by three injections per week for an additional 2 wk. Control mice were given injections of 35 µg BSA, which is equal to the amount of BSA carrier protein included in the IL-25 preparation. The amount of cytokine administered was based on the minimum dose of IL-25 that induced a prominent Th2 immune response (8).

Mouse hepatocyte preparation and treatment

Mouse primary hepatocytes were isolated from HFD-fed obese mice using a two-step collagenase perfusion method (15). Hepatocytes were seeded at
1 × 10^6 cells/well in six-well collagen-coated plates in DMEM supplemented with 5% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 4 μg/ml insulin, and 1 μmol dexamethasone. After 4 h of attachment at 37°C in a humidified atmosphere of 5% CO2, the medium was changed to DMEM without FBS, and cells were cultured for another 24 h before treatment with IL-25 or IL-13. Medium was replaced on a daily basis.

**RNA extraction, cDNA synthesis, real-time quantitative PCR, and ELISA**

Total RNA was extracted with TRIzol reagent (Invitrogen, Grand Island, NY) per the manufacturer’s instructions. RNA samples (2 μg) were reverse transcribed to cDNA using the First Strand cDNA Synthase Kit (MBI Fermentas, Hanover, MD) with random hexamer primer. Quantitative PCR (qPCR) was performed on an iCycler detection system (Bio-Rad, Hercules, CA) in a 25 μl volume using SYBR Green Supermix (Bio-Rad). Amplification conditions were: 95°C for 3 min, 50 cycles of 95°C for 15 s, 60°C for 15 s, and 72°C for 20 s. The fold change in mRNA expression for targeted gene was relative to the respective vehicle after normalization to 18s rRNA.

**Western blot analysis**

Western blot analysis was performed as described previously (19). In brief, tissue lysates prepared in RIPA buffer (Cell Signaling Technology) were separated on 14% Novex Tris-glycine Mini Gels and transferred to Novex Nitrocellulose Membrane (Life Technologies, Grand Island, NY). The tissue lysates prepared in RIPA buffer were blotted on the same day. Western blot analysis of liver tissue lysates prepared on the same day. Western blot analysis was performed as described previously (19). In brief, tissue lysates prepared in RIPA buffer (Cell Signaling Technology) were separated on 14% Novex Tris-glycine Mini Gels and transferred to Novex Nitrocellulose Membrane (Life Technologies, Grand Island, NY). The membranes were blocked with 5% milk and incubated with primary Ab against cell death–inducing DFFA-like effector A (CIDEA; 1:400; catalog number MAB1258; R&D Systems) or the isotype control. The slides were stained with Peroxidase/DAB kit (Dako Denmark) and then digitally photographed with Olympus BX51WI microscope (Olympus).

**Immunohistochemical staining on human liver sections**

Paraffin-embedded tissue slides of liver sections were acquired from a total of 14 patients. Six of them had hepatic steatosis, diagnosed initially with ultrasound examination and later confirmed by liver biopsy evaluation. The other eight patients had no hepatic steatosis and were used as control subjects. The medical history was reviewed retrospectively by a medical doctor specializing in gastroenterology and hepatology. All of the patients were >18 y old at the time of biopsy and had no history of alcohol abuse, serologic evidence of viral hepatitis, blood transfusion, or history of other competing etiologies for hepatic steatosis and coexisting causes for chronic liver disease (18). For immunohistochemical staining, slides were dewaxed with xylene, gradually washed with ethanol, blocked with goat serum, and then incubated with anti–IL-25 mAb (1:100; catalog number MAB1258; R&D Systems) or the isotype control. The slides were stained with Peroxidase/DAB kit (Dako Denmark) and then digitally photographed with Olympus BX51WI microscope (Olympus).

**Lipid extraction and analysis**

Tissue homogenates were prepared in lipid extraction buffer, shaken in the dark for 2 h, and centrifuged at 3,500 rpm for 10 min. The soluble portion was transferred to a 1.5-ml tube and dried under vacuum for 30 min. The dried lipids were made soluble in TG assay buffer by vortexing until the lipids were homogeneous. Levels of hepatic TG were determined using a commercial kit (Cayman Chemical, Ann Arbor, MI).

**Immunofluorescent staining on mouse liver sections**

Tissue sections (5 μm) were cut from frozen blocks of mouse liver and stained with H&E for histological analysis. Slides were graded for steatosis according to the Kleiner system by an investigator who was unaware of the treatment and mouse genotype (16). A score of 0–3 was assigned to describe the extent of steatosis based on lipid accumulation in the hepatocytes (0, <5%; 1, 5–33%; 2, 33–66%; and 3, >66%). Immunofluorescent staining of mouse liver sections was carried out as described previously (17). Briefly, the slides were blocked with 5% normal donkey serum and then incubated with anti-F4/80 (BioLegend) and anti–YM-1 (R&D Systems) Abs overnight. The slides were stained with Dylight 488–donkey anti-rabbit secondary Ab (Santa Cruz Biotechnology, Santa Cruz, CA) in a 25 μl volume using SYBR Green Supermix (Bio-Rad). Amplification conditions were: 95°C for 3 min, 50 cycles of 95°C for 15 s, 60°C for 15 s, and 72°C for 20 s. The fold change in mRNA expression for targeted gene was relative to the respective vehicle after normalization to 18s rRNA.

**H&E and immunofluorescent staining on mouse liver sections**

Tissue sections (5 μm) were cut from frozen blocks of mouse liver and stained with H&E for histological analysis. Slides were graded for steatosis according to the Kleiner system by an investigator who was unaware of the treatment and mouse genotype (16). A score of 0–3 was assigned to describe the extent of steatosis based on lipid accumulation in the hepatocytes (0, <5%; 1, 5–33%; 2, 33–66%; and 3, >66%). Immunofluorescent staining of mouse liver sections was carried out as described previously (17). Briefly, the slides were blocked with 5% normal donkey serum and then incubated with anti-F4/80 (BioLegend) and anti–YM-1 (R&D Systems) Abs overnight. The slides were stained with Dylight 488–donkey anti-rabbit secondary Ab (Santa Cruz Biotechnology, Santa Cruz, CA) in a 25 μl volume using SYBR Green Supermix (Bio-Rad). Amplification conditions were: 95°C for 3 min, 50 cycles of 95°C for 15 s, 60°C for 15 s, and 72°C for 20 s. The fold change in mRNA expression for targeted gene was relative to the respective vehicle after normalization to 18s rRNA.

**Western blot analysis**

Western blot analysis was performed as described previously (19). In brief, tissue lysates prepared in RIPA buffer (Cell Signaling Technology) were separated on 14% Novex Tris-glycine Mini Gels and transferred to Novex Nitrocellulose Membrane (Life Technologies, Grand Island, NY). The membranes were blocked with 5% milk and incubated with primary Ab against cell death–inducing DFFA-like effector A (CIDEA; 1:200; Cell Signaling Technology) overnight. Bands were detected using an HRP-conjugated goat anti-rabbit secondary Ab (Santa Cruz Biotechnology, Santa Cruz, CA).
The Western blot was reprobed with anti-GAPDH as a loading control.

**Statistical analysis**

Statistical analysis was performed using one-way ANOVA followed by Newman-Keuls test to compare the difference among three or more treatment groups or the Student t test to compare the difference between two groups. The p values <0.05 were considered significant.

**Results**

**HFD-induced hepatic steatosis is associated with decreased expression of IL-25 in the liver**

Hepatocytes are capable of producing IL-25, and decreased hepatic IL-25 expression has been reported in humans or mice with hepatitis (14). We established an HFD-induced model of hepatic steatosis in mice and evaluated a role of IL-25 in NAFLD. As expected, C57BL/6 mice fed the HFD for 14 wk had significantly enlarged livers and increased levels of hepatic TG (Fig. 1A, 1B), characteristics of steatosis, when compared with age- and sex-matched mice fed an NCD. Evaluation of the H&E-stained liver sections indicated that HFD-fed mice had a high degree of steatosis accompanied by the presence of both large and small fat vacuoles (Fig. 1C). In addition, steatotic livers from HFD-fed mice had significantly upregulated gene expression of lipid droplet (LD)–associated proteins including the CIDE proteins Cidea, Cideb, Cidec, as well as perilipin 2 (Plin2) (Fig. 1D). Hepatic expression of F4/80 (Emr1) and Cd11b (Fig. 1E), the markers for Kupffer cells (20, 21), were comparable between mice fed the NCD and HFD. A significant upregulation of Tnfα and Ccl2, but not Il6, was also observed in the livers of HFD-fed mice (Fig. 1E). Interestingly, HFD-fed mice had a significantly decreased IL-25 protein in the livers when compared with NCD-fed mice (Fig. 1F).

**Exogenous IL-25 ameliorates HFD-induced hepatic steatosis**

We next determined if exogenous IL-25 ameliorates HFD-induced hepatic steatosis. To this end, mice were fed the HFD for ~14 wk and then administered either IL-25 or BSA. After a 3-wk treatment, mice receiving IL-25 had significantly reduced hepatic steatosis indicated by decreased liver mass and hepatic TG levels (Fig. 2A, 2B). The amelioration was further confirmed by histological evaluation of H&E-stained liver sections showing decreased size/number of fat vacuoles and lower steatosis score (Fig. 2C, 2D). In addition, IL-25 treatment did not alter significantly the liver mass or TG levels in mice fed the NCD (Fig. 2). Of note, IL-25 decreased food intake in both groups of NCD- and HFD-fed mice in the first week of injection, but induced loss of body weight and decrease in hepatic lipid accumulation only in HFD-fed mice (Supplemental Fig. 1). This suggests that the transient decrease in food intake was unlikely a major factor for the loss of body weight or the amelioration of hepatic steatosis in IL-25–treated HFD-fed mice.

To dissect the lipid metabolic pathways that might contribute to IL-25–induced improvement in hepatic steatosis, we analyzed expression of genes encoding key enzymes for lipid metabolism. IL-25 treatment did not alter hepatic expression of key lipogenic enzymes (Fasn, Acly, and Acaca), lipid transporters (Cd36, Fatp2, and Fatp5), hepatic lipase (Lipc), or carnitine palmitoyltransferase 1a, whereas it significantly increased the expression of hydroxyacyl–CoA dehydrogenase (Hadh), an enzyme important for fatty acid (FA) oxidation (Fig. 3A, 3B, and data not shown). In addition, IL-25 treatment significantly decreased expressions of the CIDEs as well as Plin2 in the livers of HFD-fed mice (Fig. 3C). The decrease in CIDEA protein in the livers of IL-25–treated mice was further confirmed by Western blot (Fig. 3D). Hepatic expression of these LD-associated proteins was not

![Figure 3](http://www.jimmunol.org/)

**Figure 3.** Administration of IL-25 to HFD-fed mice alters the expressions of key enzyme for lipid metabolic pathway and LD-associated proteins in the liver. Mice were fed the HFD or NCD and then injected with IL-25 or BSA. qPCR was carried out to examine gene expression of lipogenic enzymes (A), FA oxidation proteins (B), and LD-associated proteins (C). CIDEA protein was detected by Western blot, and the density represents average of the bands after normalization to GAPDH (D). Data shown in bar graphs are mean ± SEM and representative of two independent experiments with five mice per group per experiment. *p < 0.05 versus respective BSA treated.
significantly altered by IL-25 treatment in NCD-fed mice, possibly due to the low constitutive expression of these genes (data not shown). These data suggest that increased FA oxidation and altered LD formation may contribute to the effects of IL-25 on hepatic steatosis.

Exogenous IL-25 induces expression of type 2 cytokine and alternative activation of Kupffer cell/macrophage in the liver

Consistent with a role of IL-25 in promoting type 2 immunity, there was an upregulation of major type 2 cytokine gene expression of Il13 and Il5 in the livers of HFD-fed mice receiving IL-25 (Fig. 4A). ILC2 are the major IL-25-responsive/IL-13-producing cells in the liver (22). Accordingly, IL-25 injection increased the expression of major ILC2 markers (6) including CD25 (Il2ra), CD90 (Thy1), CD127 (Il7r), and Sca-1 (Ly6a) as well as the transcription factor retinoic acid-related orphan receptor α in the liver (Fig. 4A). Other type 2–related cytokines—Il4, Il25, and Il33—were expressed either at relatively low levels in the liver or unaffected by treatment with IL-25 (data not shown). In contrast, IL-25 treatment significantly decreased the expression of Ccl2, but not Tnfa or Il6, in the livers of HFD-fed mice (Fig. 4B). Upregulation of Il5 and Il13 as well as a downregulation of Ccl2 were also detected in the livers of IL-25–treated NCD-fed mice (Supplemental Fig. 2A).

Kupffer cells in the liver are derived from either intrahepatic precursors or infiltrating monocytes (23) and play an important role in obesity-induced hepatic steatosis (24). IL-25 treatment did not affect the gene expression of F4/80 (Emr1), but significantly upregulated the expression of alternatively activated (M2) Kupffer cell markers arginase I (Arg1), YM-1 (Chi3l3), and found in

![FIGURE 4](http://www.jimmunol.org/) Administration of IL-25 to HFD-fed mice induces a type 2 cytokine (Cyto.) response and alternative activation of Kupffer cell/macrophage in the liver. Mice were fed an HFD and then received injections of IL-25 or BSA. (A) Hepatic expression of type 2 cytokines and molecular markers for ILC2. (B and C) Hepatic expression of proinflammatory cytokines/mediators and markers for Kupffer cell/macrophage activation. (D) Immunofluorescent staining of liver sections with anti-F4/80 (green) and anti-YM-1 (red). The images are representatives of five mice in each group (original magnification ×200). Data shown in bar graphs are mean ± SEM and representatives of two independent experiments with five mice per group per experiment. *p < 0.05 versus respective BSA-treated.
inflammatory zone (FIZZ) 1 (Retnla) (Fig. 4C). Increased number of M2 Kupffer cells/macrophages in the liver was validated further by immunofluorescent staining with anti–YM-1, as more F4/80+/YM-1+ cells could be visualized in the livers from IL-25–treated HFD-fed mice than in those from BSA-treated mice (Fig. 4D). Likewise, M2 markers were upregulated by IL-25 administration in the livers of NCD-fed mice (Supplemental Fig. 2B).

Amelioration of hepatic steatosis induced by IL-25 depends upon STAT6 and IL-13

The increased expression of IL-13 and number of M2 Kupffer cells/macrophages in the livers of HFD-fed mice injected with IL-25 prompted us to investigate whether the IL-13–STAT6 axis mediated the beneficial effects of IL-25. Thus, WT and STAT6−/− mice were fed the HFD or NCD for 14 wk and then treated with IL-25 or BSA. IL-25 administration to either NCD- or HFD-fed STAT6−/− mice had no effect on liver mass or hepatic TG levels (data not shown and Fig. 2), IL-25 injection also did not impact histological steatosis grade of HFD-fed STAT6−/− mice (Fig. 5C). qPCR showed that IL-25 injection induced upregulation of Il5 and IL13 in the livers of HFD-fed STAT6−/− mice (Fig. 5D) comparable to that of WT mice (Fig. 4A). However, the IL-25–induced upregulation of M2 Kupffer cell markers Arg1 and YM-1 (Chi3l3) in WT mice (Fig. 4B, 4C) was almost absent in STAT6−/− mice (Fig. 5D) consistent with a STAT6 dependence. Immunofluorescent staining with anti–YM-1 confirmed no increase in the number of M2 Kupffer cells in the livers of IL-25–treated-STAT6−/− mice (data not shown). In addition, the IL-25–induced alterations in hepatic expression of Cideb, Cidec, Plin2, Hadh, or Ccl2 in WT mice (Figs. 3C, 4A) were absent in STAT6−/− mice, with the exception of Cidea, which remained downregulated (Fig. 5E, Supplemental Fig. 3).

Exogenous IL-25 can increase the expression of IL-4 and IL-13 (9, 10), both of which activate the STAT6 pathway; therefore, parallel experiments were carried out to determine the contribution of IL-13 to the effects of IL-25 on hepatic steatosis. In IL-13−/− mice fed the HFD for 14 wk, IL-25 treatment for 3 wk had no effect on liver mass, hepatic TG level, or lipid accumulation (Fig. 6A, 6B). There was also no increase in the number of M2 Kupffer cells in the livers of IL-25–treated IL-13−/− mice, indicated by the similar transcript levels of the markers (Arg1 and Retnla) between mice injected with BSA and IL-25 (Fig. 6C) and confirmed by immunofluorescent staining of liver section with anti–YM-1 (data not shown). Among the LD-associated proteins in the livers of IL-13−/− mice, IL-25 did not affect the expression of Cideb and Plin2, but surprisingly induced a modest upregulation of the expression of Cidea and Cidec (Fig. 6D) contrary to that observed in WT mice (Fig. 3C).

The in vivo results indicated that the IL-13–STAT6 axis plays a critical role in the IL-25–induced amelioration of hepatic steatosis, likely through inhibiting expression of LD-associated proteins. Whether IL-13 directly acts on hepatocytes was examined further in primary culture of mouse hepatocytes. qPCR analysis showed that IL-13 treatment of hepatocytes significantly downregulated the expression of Cidea, Cideb, and Plin2, whereas it had no effect on the expression of Cidec (Fig. 6E). Of note, IL-13 treatment did not
alter the gene expression of the LD-associated proteins described above in the hepatocytes isolated from STAT6/−/− mice (data not shown). In contrast, IL-25 had no direct effect on the expression of any of the LD-associated proteins examined (Fig. 6E).

Genetic deletion of IL-25 increases susceptibility to HFD-induced steatosis

The potent effects of exogenous IL-25 on HFD-induced hepatic steatosis led us to examine further whether endogenous IL-25 is important for maintaining lipid metabolic homeostasis. Thus, WT and IL-25+/− mice were fed the HFD or NCD for ~16 wk. When compared with age- and sex-matched WT mice, both NCD- and HFD-fed IL-25+/− mice had lower body weights (Fig. 7A). No significant differences in the liver mass or hepatic TG levels were detected between the two strains of mice fed the NCD (Fig. 7B, 7C). However, HFD-fed IL-25+/− mice had enlarged livers that were macroscopically pale in color (Fig. 7B, 7D) and increased levels of hepatic TG (Fig. 7C) as compared with their WT counterparts, although histological analysis was unable to reveal a significant difference statistically in steatosis (Fig. 7E) because of insufficient sensitivity of the grading system. The exacerbated hepatic steatosis in HFD-fed IL-25+/− mice was associated with upregulated expressions of Cidea, Cideb, Cidec, as well as Plin2 (Fig. 7F).

Hepatic IL-25 expression is reduced in patients with fatty liver

To investigate the clinical relevance of our findings from mouse studies, we performed immunohistochemical staining with anti-IL-25 on paraffin-embedded liver sections from patients with or without fatty liver. IL-25–positive hepatocytes were visualized clearly in the liver sections from both groups of patients (Fig. 8). However, IL-25 staining was dramatically less in patients with fatty liver compared with those without. This is consistent with the ELISA results (Fig. 1F) showing decreased IL-25 protein in the livers of HFD-fed mice.

Discussion

Immune components play an important role in the development of hepatic steatosis, yet much of the focus has been on proinflammatory cytokines with less attention to anti-inflammatory immune mediators. Type 2–related cytokines, including IL-25, are capable of counterregulating Th1 and Th17 immunity. Results from our current study indicate that exogenous IL-25 potently ameliorates the hepatic steatosis induced by HFD feeding through IL-13 activation of STAT6, whereas genetic deletion of IL-25 renders mice more susceptible to HFD-induced lipid accumulation in the liver. These results reveal a previously unrecognized role for IL-25 in the regulation of lipid metabolism.

IL-25 belongs to the IL-17 cytokine family (3). IL-17A, another key member of the family, was identified as a central player to the development and progression of NAFLD to steatohepatitis (25–27). Our results, however, show that IL-25 has beneficial effects against NAFLD, which is consistent with the established anti-inflammatory role for IL-25. Gut and lung epithelial cells are the recognized cellular sources for IL-25 (9, 10). Several types of immune cells may also produce IL-25 under certain circumstances, including Th2 cells, mast cells, and macrophages (8, 11–13). A recent study further identified
hepatocytes as IL-25–expressing cells (14). Our current study showed that lipid accumulation in the liver was accompanied by decreased levels of IL-25 protein indicative of a role in regulation of lipid metabolism. Indeed, administration of IL-25 to HFD-fed WT mice resulted in a significant improvement in hepatic steatosis. Lipid accumulation in the liver arises from the imbalance of lipid acquisition and disposal; therefore, impaired FA oxidation, decreased lipid export, and increased de novo lipogenesis in the liver are considered the key determinants of hepatic steatosis. Our results showed that IL-25 treatment did not affect hepatic expressions of key enzymes for lipogenesis or lipid export, but increased the expression of Hadh, an enzyme critical for FA oxidation, implicating one of the potential mechanisms for amelioration of steatosis by IL-25.

LDs are cytosolic lipid storage organelles present in nearly all cell types, and abnormal LD formation contributes to various human diseases including NAFLD (28). In hepatocytes, the size and number of TG-containing LDs are regulated by several types of proteins referred to as LD-associated proteins including members of CIDE and PLIN families. Both CIDEs and PLINs, especially the highly expressed PLIN2 in the liver, are believed to be the important regulators of lipid storage and formation of LDs in hepatocytes (29). Multiple lines of research demonstrated that mice or humans with hepatic steatosis have increased expression of LD-associated proteins in the liver (28). In addition, mice deficient in either one of the CIDEs exhibit decreased lipid accumulation and reduced hepatic steatosis when fed an HFD. In contrast, overexpression of CIDEA in mouse liver leads to increased hepatic lipid accumulation (30). Mice with PLIN2 deficiency are protected also from HFD-induced fatty liver disease accompanied by decreased adiposity (31). Consistent with previous observations, we observed that HFD-induced hepatic steatosis was associated with increased expression of all members of the CIDE family and PLIN2. More importantly, treatment with IL-25 ameliorated hepatic steatosis and was accompanied by significantly decreased gene expression of Cidea, Cideb, Cidec, and Plin2. Conversely, IL-25/−/− mice had increased hepatic levels of LD-associated proteins. These results strongly support that IL-25 regulates the expression of LD-associated protein, thereby controlling lipid accumulation in the liver.

Kupffer cells/macrophages in the liver represent ∼10% of the resting total liver cell population and >80% of all tissue macrophages in the body (32). Traditional roles of Kupffer cells include launching biochemical attack, recruiting immune cells to the liver, eliminating cell debris and microorganisms, as well as Ag presentation. Kupffer cells are implicated in the pathogenesis of various liver diseases including hepatitis, alcoholic liver disease, and liver fibrosis (32). Like all macrophages, Kupffer cells undergo distinct pathways of activation and display different phenotypes depending on the cytokine microenvironment. Classically activated (M1) Kupffer cells are induced by Th1 cytokines and characterized by upregulation of inducible NO synthase, whereas M2 Kupffer cells are induced by Th2 cytokines IL-4 and IL-13 and feature highly upregulated Arg1 as well as the secretion of chitinase and FIZZ family members such as YM1, FIZZ1, and FIZZ2 (33). Emerging evidence indicates that differentially activated Kupffer cells play distinctive roles in the progression of NAFLD. Specifically, M1 Kupffer cells produce proinflammatory cytokines, such as IL-1β and TNF-α, which inhibit peroxisome proliferator–activated receptor α activity, leading to decreased

**FIGURE 7.** Mice with genetic deletion of IL-25 are more susceptible to HFD-induced hepatic steatosis. WT and IL-25−/− mice were fed an HFD or NCD diet. (A) Body weight. (B) Liver mass. (C) Liver TG level. (D) Gross appearance of the liver; representative H&E-stained liver sections (original magnification ×100). (E) Steatosis scores. (F) Hepatic expression of LD-associated proteins by qPCR. Data are mean ± SEM and are representatives of two independent experiments with five to eight mice per group. *p < 0.05 versus respective NCD (A–C) or WT-HFD (F), †p < 0.05 versus respective WT.
expression of genes involved in FA oxidation (24, 34). Depletion of Kupffer cells with clodronate liposomes reduces HFD-induced steatosis (24, 34). In contrast, M2 Kupffer cells promote M1 Kupffer cell apoptosis through activation of arginase, thereby protecting against NAFLD (35). Our results showed that mice treated with IL-25 exhibited a polarized type 2 immunity characterized by upregulations of IL-5 and IL-13, which led to development of M2 Kupffer cells in the liver. Thus, it is conceivable that the beneficial effects of IL-25 on steatosis are derived, at least in part, through its ability to promote a type 2 environment, particularly increasing IL-13 that can lead to development of M2 Kupffer cells, as demonstrated previously (36, 37). It should be noted that Kupffer cells/macrophages in the liver are a heterogeneous population (23). It remains to be determined whether the IL-25–induced M2 development occurred in the resident Kupffer cells, the infiltrated monocytes/macrophages, or both.

IL-25 induces increased expression of IL-4 and IL-13 that primarily activate the STAT6 pathway, as well as IL-5 that elicits eosinophilia (9, 38). Consistent with these observations, mice treated with IL-25 had increased gene expression of il5 and il13 but negligible levels of il4 in the liver. Notably, the amelioration of hepatic steatosis induced by exogenous IL-25 depended on STAT6 or IL-13, indicating that IL-25 acts through IL-13 activation of STAT6 signaling to regulate lipid accumulation in the liver. Hepatocytes are known to express receptors for IL-25 in vivo (42). Thus, it is likely that IL2 are the IL-13–producing cells that mediate the IL-25 effects on hepatic steatosis.

Mice deficient in IL-25 develop intestinal inflammation in response to enteric nematode infection, characterized by increased expression of IL-17A as well as defective type 2 immune response (10). Hepatocytes can make IL-25, and decreased expression of IL-25 in the liver is observed in animals or human with hepatitis (14). Our results show that there is an increased severity of steatosis in mice with IL-25 deficiency accompanied by high levels of LD-associated proteins. Finally, the observation that patients with NAFLD had decreased immunostaining of IL-25 in the livers demonstrates the clinical importance of hepatic expression of IL-25. The mechanisms by which IL-25 was decreased in steatosis remain to be investigated; however, the decrease in IL-25 was accompanied by an increase in TNF-α in steatotic livers, and TNF-α was shown to negatively regulate IL-25 expression in the colon or brain (43). More studies are needed to ascertain whether this same mechanism of TNF-α regulating IL-25 occurs in the liver.

Taken together, our study is the first, to our knowledge, to show that IL-25 is important in maintaining lipid metabolic homeostasis in the liver. Even though the detailed mechanism remains to be fully understood, it is believed that IL-25 in the liver stimulates ILC2 to release IL-13 that in turn acts on hepatocytes as well as Kupffer cells via STAT6-dependent pathways, which then altered the expression of proinflammatory mediators, LD-associated proteins.
proteins, and factors that control lipid metabolic pathways. These combined effects of IL-25 led to attenuated hepatic steatosis (Supplemental Fig. 4). Conversely, IL-25 deficiency caused exacerbation of hepatic lipid accumulation in HFD-fed mice. These results implicate IL-25 and the downstream type 2 cytokines as potential therapeutic agents for control of human hepatic steatosis and associated pathologies.

Disclosures

The authors have no financial conflicts of interest.

References


